Johns Hopkins HIV Guide
Ribavirin
INDICATIONS
FDA
FDA
- Hepatitis C in combination with direct-acting antivirals (e.g. sofosbuvir, simeprevir, daclatasvir, etc.) or interferon alpha or peginterferon alpha
- Respiratory syncytial virus (RSV) infection (including bronchiolitis and pneumonia) [inhalation formulation only]
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Treatment of progressive vaccinia in combination with vaccinia immune globulin (VIG)[12].
- Treatment of hemorrhagic fever.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: March 5, 2023
Citation
Smith, Janessa M. "Ribavirin." Johns Hopkins HIV Guide, 2023. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545181/11/Ribavirin.
Smith JM. Ribavirin. Johns Hopkins HIV Guide. 2023. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545181/11/Ribavirin. Accessed November 30, 2023.
Smith, J. M. (2023). Ribavirin. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545181/11/Ribavirin
Smith JM. Ribavirin [Internet]. In: Johns Hopkins HIV Guide. ; 2023. [cited 2023 November 30]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545181/11/Ribavirin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Ribavirin
ID - 545181
A1 - Smith,Janessa,PharmD, BCPS
Y1 - 2023/03/05/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545181/11/Ribavirin
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
